SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rezolve AI Plc operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. It develops AI-based mobile commerce and engagement solutions, simplifying the purchasing process by providing relevant information and facilitating seamless transactions with a single tap. The company enables retailers, brands, and manufacturers to create dynamic connections with consumers across mobile and desktop devices. Rezolve Ai was founded in 2016 and is headquartered in London, the United Kingdom.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI (RZLV) is trending as investors discuss the implications of a recent $200 million private placement just days before earnings, with community members debating whether it signals confidence or dilution. Some investors express concerns about the timing and potential stock impact, while others view it as a strategic move for growth and expansion. The community is also actively discussing the upcoming earnings report and potential partnerships.

BTQ Technologies Corp

BTQ Technologies is trending due to discussions around its recent Nasdaq uplisting and the potential for dilution, creating volatility. The community is debating the company's valuation, future revenue, and potential partnerships in the quantum cybersecurity space. Some investors are drawing comparisons to other stocks with similar trajectories, while others remain optimistic about its long-term prospects in the emerging quantum security market.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to news of a land sale agreement potentially boosting its NAV, sparking interest in its low float. The community is discussing potential for a significant price increase, with some eyeing a breakout and possible short squeeze. Some traders are comparing it to other low float runners and highlighting the company's liquidation plans.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as investors discuss the stock's recent price action and potential catalysts, including government funding and rare earth demand. Community members are debating entry points, technical levels, and the impact of broader market conditions. Some traders are expressing concerns about potential shorts and government funding, while others remain bullish on the company's long-term prospects in the rare earth sector.

The project is a derivative of Fartcoin. The Fartcoin deployer has deployed this token because the President at Bone Fide Wealth tweeted about "A client just called and asked me if there’s going to be a Fartcoin ETF this year." Since the Elon narrative is has been running this one has come to existence. The token is following different narratives like Fartcoin, SPX500 and other big memes following the Trump narrative.

Elon Trump Fart

ETF500.X is trending as the community rallies behind it, touting it as the first ETF on Solana. Many are calling for accumulation and holding, anticipating a meme season and significant gains. Some users are expressing concerns, while others highlight the strength and potential of the community-driven fund.

Electronic Arts, Inc. engages in the development, marketing, publication, and distribution of games, content, and services for game consoles, PCs, mobile phones, and tablets. The company develops and publishes games and services across various genres, such as sports, first-person shooter, action, role-playing, and simulation primarily under the Battlefield, The Sims, Apex Legends, Anthem, Need for Speed, and Plants v. Zombies brands, and license games, including FIFA, Madden NFL, and Star Wars brands. The firm also provides advertising services and licenses its games to third parties to distribute and host its games. It markets and sells its games and services through digital distribution channels, as well as through retail channels, such as mass-market retailers, electronics specialty stores, and game software specialty stores. The company was founded by William M. Hawkins III and William Gordon in 1982 and is headquartered in Redwood City, CA.

Electronic Arts, Inc.

Electronic Arts stock is trending due to reports that the videogame giant may go private in a deal potentially valued at $50 billion, with Silver Lake and Saudi Arabia's Public Investment Fund mentioned as part of the investor consortium. The community is actively discussing the potential deal's impact on game quality and the future direction of EA's popular franchises, with some expressing hope for improved games if the deal goes through.

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Enanta Pharmaceuticals Inc

$ENTA is trending as investors discuss upcoming Phase 2 data on their RSV treatment, expected on Monday, sparking speculation of positive results and a potential rocket move; the community also highlights the company's strong financial position and potential for significant gains in the antiviral space.

Carnival Corp. engages in the operation of cruise ships. It operates through the following business segments: North America and Australia (NAA) Cruise, Europe and Asia (EA) Cruise Operations, Cruise Support, and Tour and Others. The North America and Australia (NAA) Cruise segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe and Asia (EA) Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corp. - Ordinary Shares (Paired Stock)

Carnival Corp

CCL is trending as investors anticipate upcoming earnings, driven by expectations of lower fuel costs, increased bookings, and positive analyst ratings. Community talking points revolve around potential price targets and whether the stock's rise is based on its own merits or tracking the broader market. Some traders are noting heavy options flow and caution against potentially overblown post-COVID vacation demand.

Hang Feng Technology Innovation Co Ltd

Hang Feng Technology Innovation Co Ltd is trending as traders discuss its recent gains and potential continued momentum. Community members are speculating on resistance levels and the impact of potential revenue from a partnership. Some traders are also drawing comparisons to other Chinese IPOs.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two Interactive is trending as community members discuss its potential following news of Electronic Arts exploring going private, with some suggesting mergers within the gaming sector. Investors are weighing the potential impact of the upcoming GTA 6 release, debating whether its success is already factored into the stock's valuation. Bullish sentiment remains due to anticipation for GTA 6 and the belief it will drive significant revenue.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Amneal Pharmaceuticals (AMRX) said on Tuesday that its generic equivalent of AbbVie's (ABBV) eyedrops received approval from the U.S. Food and Drug Administration.The company’s Bimatoprost ophthalmic solution 0.01% is <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.amneal.com/news/press-releases/press-release-details/2025/Amneal-Receives-U-S--FDA-Approval-for-Bimatoprost-Ophthalmic-Solution-0-01/default.aspx">indicated</a> for reducing high eye pressure in patients with open-angle glaucoma or ocular hypertension. It is a generic equivalent of LUMIGAN 0.01%, whose design is a trademark of AbbVie’s Allergan.Shares of the company rose 5% in the pre-market session at the time of writing. On Stocktwits, the retail sentiment around <a href="https://stocktwits.com/symbol/AMRX">AMRX stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.The New Jersey-headquartered company said the most common adverse reaction associated with the use of eyedrops is conjunctival hyperemia or redness of the eye. The company expects the solution to be a key growth driver for its Affordable Medicines portfolio.“As the prevalence of glaucoma continues to rise, particularly among the aging population, it is critical that patients and providers have affordable access to effective treatments such as bimatoprost. This represents our most recent complex new product approval this year…,” company executive Srinivas Kone said. Open-angle glaucoma is a progressive eye disease that involves optic nerve damage and vision loss due to high eye pressure.Earlier this month, the company also announced FDA approval for its sodium oxybate oral solution 500 mg/mL indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy. Narcolepsy is characterized by excessive daytime sleepiness, sudden sleep attacks, and cataplexy, a sudden loss of muscle control often triggered by emotions.AMRX stock is up by 26% this year and by about 17% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moderna-says-updated-mnexspike-covid-shot-demonstrated-rbust-immune-response-in-study/chDhMlcR35J">Moderna Says Updated mNEXSPIKE Covid Shot Demonstrated Robust Immune Response In Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Amneal Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Amneal Pharma Stock Rises On FDA Approval For Generic Version Of AbbVie’s Eyedrops

Amneal’s bimatoprost ophthalmic solution 0.01% is indicated for the reduction of high eye pressure in patients with certain eye conditions.

Equity

Amneal’s bimatoprost ophthalmic solution 0.01% is indicated for the reduction of high eye pressure in patients with certain eye conditions.


Wall Street Analysts Think Amneal (AMRX) Could Surge 25.52%: Read This Before Placing a Bet

The consensus price target hints at a 25.5% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Rigel Pharmaceuticals, Inc. (RIGL) Soars to 52-Week High, Time to Cash Out?

Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Wall Street Analysts See a 27.66% Upside in Amneal (AMRX): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 27.7% in Amneal (AMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Are Medical Stocks Lagging  Boston Scientific (BSX) This Year?

Here is how Boston Scientific (BSX) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Here's Why Momentum in Amneal (AMRX) Should Keep going

If you are looking for stocks that are well positioned to maintain their recent uptrend, Amneal (AMRX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Amneal (AMRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates

Amneal (AMRX) delivered earnings and revenue surprises of +38.89% and -0.15%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?

VTRS braces for Q2 results as branded drug growth in Europe and China offsets generic headwinds in North America.

Nektar Gears Up to Report Q2 Earnings: What's in the Cards?

NKTR is due to report second-quarter results. Investors await fresh updates on rezpeg's progress across autoimmune trials.

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Current Price	$9.75
Prev Close	$9.60
Open	$9.72
Dividend Yield	0.00%
50-Day Moving Average	$9.06
Beta	1.21
Avg. Volume	1.69M
PE Ratio	1,500.00

52-Week High	$10.34
52-Week Low	$6.69
Market Capitalization	$3.02B
EPS (Annual)	-$0.3783
Price to Book	-26.89
Revenue Per Employee	$336,621.33
Enterprise Value/EBITDA	N/A

AMRX
Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AMRX News

AMRX Amneal Pharmaceuticals Inc - Ordinary Shares - Class A